Exscientia Agrees to Acquisition by Recursion Pharmaceuticals
Company Announcements

Exscientia Agrees to Acquisition by Recursion Pharmaceuticals

Exscientia Plc (EXAI) has released an update.

Exscientia plc, an England and Wales incorporated public limited company, has entered into a transaction agreement on August 8, 2024, with Recursion Pharmaceuticals, Inc. The agreement outlines the acquisition of Exscientia by Recursion Pharmaceuticals through a Scheme of Arrangement, which is considered fair and in the best interests of the shareholders by Exscientia’s board of directors.

For further insights into EXAI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskExscientia Plc Faces Financial Challenges Amid Rising Costs
TipRanks Auto-Generated NewsdeskExscientia Plc Enhances Board Collaboration with Recursion
TheFlyExscientia advances two additional discovery programs with Sanofi
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App